|
시장보고서
상품코드
2023541
유행성이하선염 백신 시장 분석 및 예측(-2035년) : 용도, 백신 유형, 투여 경로, 유통 채널Mumps Vaccine Market Analysis and Forecast to 2035: Application, Vaccine Type, Route of Administration, Distribution Channel |
||||||
세계의 유행성이하선염(볼거리) 백신 시장은 2025년 28억 달러에서 2035년까지 52억 달러로 확대하며, CAGR은 6.1%에 달할 것으로 예측됩니다. 유행성이하선염 백신 시장은 예방접종에 대한 자금 투입 증가와 안정적인 인구 통계학적 요인에 따른 수요에 힘입어 성장하고 있습니다. 각국 정부는 미국 질병예방통제센터(CDC)가 주도하는 프로그램을 통해 백신 조달을 확대하고 있으며, 미국에서는 연간 약 360만 명에 달하는 안정적인 출생 코호트가 기초 수요를 지원하고 있습니다. 전염병 감시가 강화됨에 따라 특히 인구 밀집 지역에서 추가 접종 캠페인이 추진되고 있습니다. 또한 세계보건기구(WHO)가 보고하는 전 세계 홍역 재유행으로 인해 MMR 백신 접종률이 향상되고 있습니다. 취학 전 예방접종에 대한 규제 집행 강화와 콜드체인 인프라 개선으로 안정적인 공급, 폐기물의 감소, 그리고 지역 전체의 백신 접종률 향상을 더욱 확실하게 보장하고 있습니다.
세계의 유행성이하선염(볼거리) 백신 시장에서 백신 유형 부문은 항원 구성에 따라 단가 백신, 3가 백신, 4가 백신으로 분류됩니다. 3가 및 4가 백신은 한 번의 접종으로 여러 질병에 대한 예방 효과를 제공하고 예방접종 효율과 접종률을 향상시키기 때문에 시장을 독점하고 있습니다. 2025년에는 3가 및 단가 백신 카테고리가 약 15억 1,500만 달러를 차지할 것으로 예상됩니다. MMR, MMRV 등 혼합백신은 주사 횟수를 줄이고 접종 순응도를 높이기 위해 각국의 예방접종 프로그램에서 널리 채택되고 있습니다. 소아 예방접종과 공중보건에 대한 관심이 높아지면서 전 세계에서 다가백신에 대한 수요가 지속적으로 증가하고 있습니다.
세계의 유행성이하선염(볼거리) 백신 시장에서 투여 경로 부문은 피하 및 근육내 투여를 포함합니다. 피하 투여는 MMR과 같은 생백신 투여에 널리 사용되므로 이 부문을 지배하고 있으며, 2025년에는 약 20억 3,230만 달러에 달할 것으로 예상됩니다. 이 방법은 항원의 흡수를 제어할 수 있으며, 전 세계 정기적인 소아 예방접종 일정에 일반적으로 사용되고 있습니다. 근육내 투여도 효율적인 면역 반응과 표준화된 투여 절차로 인해 임상 현장과 병원에서 널리 사용되고 있습니다. 전 세계 백신 접종률 향상과 예방접종 가이드라인 준수에 따라 효과적인 질병 예방을 위해 두 가지 투여 경로 모두에 대한 수요가 증가하고 있습니다.
지역별 개요
2025년 북미는 전 세계 유행성이하선염 백신 시장을 주도하며 전체 매출 점유율의 약 39.0%를 차지할 것으로 예상됩니다. 이러한 성장은 미국과 캐나다에서 반복되는 유행성이하선염의 유행과 공중 보건 측면에서의 강력한 대응에 힘입은 바 큽니다. 확진자 증가와 예방접종 면제율 증가에 따라 당국은 예방접종 프로그램과 인식 개선 캠페인을 강화하고 있습니다. 동시에 소아 백신에 대한 높은 신뢰와 학교의 예방접종 요건이 안정적인 접종률을 지원하고 있습니다. 이러한 요인들이 결합되어 안정적인 수요를 보장하고, 세계 시장에서 북미의 우위를 공고히 하고 있습니다.
아시아태평양은 2026-2035년까지 CAGR 7.9%를 기록하며 가장 빠른 성장세를 보일 것으로 예상되며, 볼거리 백신 시장에서 가장 빠른 성장이 예상됩니다. 이러한 성장은 인도네시아, 싱가포르, 뉴질랜드 등의 국가에서 홍역과 유행성이하선염의 집단 감염이 증가함에 따라 MMR 백신에 대한 수요가 증가하고 있기 때문으로 분석됩니다. 정부의 의무 예방접종 프로그램과 무료 또는 보조금 지원 백신에 대한 접근성 확대로 예방접종률이 향상되고 있습니다. 또한 집단 감염에 대한 적극적인 대응 캠페인과 집단 면역에 대한 인식이 높아지면서 백신 보급이 가속화되고 있으며, 아시아태평양은 중요한 고성장 지역으로 자리매김하고 있습니다.
주요 동향 및 촉진요인
유행성이하선염 백신 시장에서 혼합백신으로의 전환:
유행성이하선염 백신 시장에서는 예방접종 보급률 향상과 접종 간소화를 위해 혼합백신과 첨단 접종 기술로의 전환이 이루어지고 있습니다. MMR과 MMRV와 같은 백신은 한 번의 접종으로 여러 질병에 대한 예방 효과를 제공함으로써 접종 순응도를 높이고 물류의 복잡성을 줄일 수 있으며, 널리 채택되고 있습니다. 세계보건기구(WHO)와 유니세프(UNICEF) 등의 지원으로 마이크로어레이 패치, 비강 스프레이, 제트 인젝터 등 바늘 없이 투여할 수 있는 혁신적인 기술이 등장하고 있습니다. 이러한 발전은 접근성을 높이고 콜드 체인에 대한 의존도를 낮추며, 특히 자원이 부족한 환경에서 전 세계 예방접종 성과를 향상시키고 있습니다.
홍역 백신 시장에서의 대규모 정부 캠페인과 국제적인 자금 지원:
볼거리 백신 시장은 정부의 대규모 예방접종 프로그램과 국제보건기구의 자금 지원으로 인해 크게 성장하고 있습니다. 세계보건기구(WHO)와 유니세프(UNICEF) 등의 기관이 참여하는 공동 구상을 통해 전 세계 수백만 명의 어린이를 대상으로 한 광범위한 예방접종 캠페인이 이루어지고 있습니다. 이러한 노력은 의료 종사자를 동원하고, 일반 시민의 의식을 높이고, 정기 예방접종 체계를 강화하는 데 기여하고 있습니다. 또한 미국 등지에서 유행성이하선염의 집단 감염이 증가함에 따라 지속적인 예방접종률 확보의 필요성이 대두되고 있습니다. 이러한 노력은 백신에 대한 접근성을 확대하고 전 세계 질병 예방을 개선하는 데 있으며, 공중보건에 대한 투자가 매우 중요한 역할을 하고 있음을 강조합니다.
목차
제1장 개요
제2장 시장 하이라이트
제3장 시장 역학
제4장 부문 분석
제5장 지역별 분석
제6장 시장 전략
제7장 경쟁 정보
제8장 기업 개요
제9장 Global Insight Services 소개
KSA 26.05.14The global mumps vaccine market is projected to grow from $2.8 billion in 2025 to $5.2 billion by 2035, at a compound annual growth rate (CAGR) of 6.1%. The mumps vaccine market is supported by rising immunization funding and stable demographic demand. Governments are expanding vaccine procurement through programs led by the Centers for Disease Control and Prevention, while consistent birth cohorts of around 3.6 million annually in the U.S. sustain baseline demand. Increasing outbreak surveillance is driving booster campaigns, particularly in high-density settings. Additionally, global measles resurgence reported by the World Health Organization is boosting uptake of MMR vaccines. Strengthened regulatory enforcement for school-entry immunization and improved cold-chain infrastructure are further ensuring stable supply, reduced wastage, and broader vaccine coverage across regions.
In the global mumps vaccine market, the vaccine type segment is categorized into monovalent, trivalent, and tetravalent vaccines based on antigen composition. Trivalent and tetravalent vaccines dominate due to their ability to provide protection against multiple diseases in a single dose, improving immunization efficiency and coverage. The trivalent and monovalent category accounted for about $1,515.0 million in 2025. Combination vaccines such as MMR and MMRV are widely adopted in national immunization programs to reduce the number of injections and enhance compliance. Growing emphasis on pediatric vaccination and public health initiatives continues to support demand for multivalent vaccines globally.
| Market Segmentation | |
|---|---|
| Application | Paediatrics, Adults |
| Vaccine Type | Tetravalent, Trivalent and Monovalent |
| Route of Administration | Subcutaneous, Intramuscular |
| Distribution Channel | Hospitals & Clinics, Vaccine Centers and Public Health Clinics, Others |
In the global mumps vaccine market, the route of administration segment includes subcutaneous and intramuscular methods. Subcutaneous administration dominates the segment due to its widespread use in delivering live attenuated vaccines such as MMR, reaching approximately $2,032.3 million in 2025. This method allows controlled antigen absorption and is commonly used in routine childhood immunization schedules worldwide. Intramuscular administration is also widely utilized in clinical and hospital settings for efficient immune response and standardized delivery practices. Increasing global vaccination coverage and adherence to immunization guidelines are driving demand for both administration routes to ensure effective disease prevention.
Geographical Overview
North America leads the global mumps vaccine market in 2025, accounting for approximately 39.0% of total revenue share. Growth is driven by recurring mumps outbreaks and strong public health responses in the United States and Canada. Increasing case reports and rising vaccine exemption rates are prompting authorities to strengthen immunization programs and awareness campaigns. At the same time, high public confidence in childhood vaccines and school immunization requirements support consistent uptake. These factors collectively ensure stable demand and reinforce North America's dominant position in the global market.
The Asia-Pacific region is projected to be the fastest-growing mumps vaccine market, registering a CAGR of 7.9% from 2026 to 2035. Growth is fueled by increasing measles and mumps outbreaks across countries such as Indonesia, Singapore, and New Zealand, which are driving demand for MMR vaccines. Government-mandated immunization programs and expanded access to free or subsidized vaccines are improving coverage rates. Additionally, proactive outbreak response campaigns and rising awareness of herd immunity are accelerating vaccine adoption, positioning Asia-Pacific as a key high-growth region.
Key Trends and Drivers
Shift Toward Combination Vaccine in the Mumps Vaccine Market:
The Mumps Vaccine Market is increasingly shifting toward combination vaccines and advanced delivery technologies to improve immunization coverage and simplify administration. Vaccines such as the MMR and MMRV formulations are widely adopted, offering protection against multiple diseases in a single dose, thereby enhancing compliance and reducing logistical complexity. Supported by organizations like World Health Organization and UNICEF, innovations such as microarray patches, intranasal sprays, and jet injectors are emerging to enable needle-free delivery. These advancements improve accessibility, reduce cold-chain dependency, and strengthen global vaccination outcomes, particularly in low-resource settings.
Large-Scale Government Campaigns and Global Funding Support in the Mumps Vaccine Market:
The Mumps Vaccine Market is significantly driven by large-scale government immunization programs and funding support from global health organizations. Collaborative initiatives involving entities such as World Health Organization and UNICEF have enabled widespread vaccination campaigns targeting millions of children worldwide. These efforts mobilize healthcare workers, enhance public awareness, and strengthen routine immunization systems. Additionally, rising incidences of mumps outbreaks in regions like the United States reinforce the need for sustained vaccination coverage. Such initiatives highlight the critical role of public health investment in expanding vaccine access and improving disease prevention globally.
Research Scope
- Estimates and forecasts the overall market size across type, application, and region.
- Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
- Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
- Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
- Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
- Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
- Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.
TABLE OF CONTENTS
1 Executive Summary
- 1.1 Market Size and Forecast
- 1.2 Market Overview
- 1.3 Market Snapshot
- 1.4 Regional Snapshot
- 1.5 Strategic Recommendations
- 1.6 Analyst Notes
2 Market Highlights
- 2.1 Key Market Highlights by Vaccine Type
- 2.2 Key Market Highlights by Route of Administration
- 2.3 Key Market Highlights by Distribution Channel
- 2.4 Key Market Highlights by Application
3 Market Dynamics
- 3.1 Macroeconomic Analysis
- 3.2 Market Trends
- 3.3 Market Drivers
- 3.4 Market Opportunities
- 3.5 Market Restraints
- 3.6 CAGR Growth Analysis
- 3.7 Impact Analysis
- 3.8 Emerging Markets
- 3.9 Technology Roadmap
- 3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTLE Analysis
4 Segment Analysis
- 4.1 Market Size & Forecast by Vaccine Type (2020-2035)
- 4.1.1 Tetravalent
- 4.1.2 Trivalent
- 4.1.3 Monovalent
- 4.2 Market Size & Forecast by Route of Administration (2020-2035)
- 4.2.1 Subcutaneous
- 4.2.2 Intramuscular
- 4.3 Market Size & Forecast by Distribution Channel (2020-2035)
- 4.3.1 Hospitals & Clinics
- 4.3.2 Vaccine Centers and Public Health Clinics
- 4.3.3 Others
- 4.4 Market Size & Forecast by Application (2020-2035)
- 4.4.1 Paediatrics
- 4.4.2 Adults
5 Regional Analysis
- 5.1 Global Market Overview
- 5.2 North America Market Size (2020-2035)
- 5.2.1 United States
- 5.2.1.1 Vaccine Type
- 5.2.1.2 Route of Administration
- 5.2.1.3 Distribution Channel
- 5.2.1.4 Application
- 5.2.2 Canada
- 5.2.2.1 Vaccine Type
- 5.2.2.2 Route of Administration
- 5.2.2.3 Distribution Channel
- 5.2.2.4 Application
- 5.2.3 Mexico
- 5.2.3.1 Vaccine Type
- 5.2.3.2 Route of Administration
- 5.2.3.3 Distribution Channel
- 5.2.3.4 Application
- 5.2.1 United States
- 5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
- 5.3.1.1 Vaccine Type
- 5.3.1.2 Route of Administration
- 5.3.1.3 Distribution Channel
- 5.3.1.4 Application
- 5.3.2 Argentina
- 5.3.2.1 Vaccine Type
- 5.3.2.2 Route of Administration
- 5.3.2.3 Distribution Channel
- 5.3.2.4 Application
- 5.3.3 Rest of Latin America
- 5.3.3.1 Vaccine Type
- 5.3.3.2 Route of Administration
- 5.3.3.3 Distribution Channel
- 5.3.3.4 Application
- 5.3.1 Brazil
- 5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
- 5.4.1.1 Vaccine Type
- 5.4.1.2 Route of Administration
- 5.4.1.3 Distribution Channel
- 5.4.1.4 Application
- 5.4.2 India
- 5.4.2.1 Vaccine Type
- 5.4.2.2 Route of Administration
- 5.4.2.3 Distribution Channel
- 5.4.2.4 Application
- 5.4.3 Japan
- 5.4.3.1 Vaccine Type
- 5.4.3.2 Route of Administration
- 5.4.3.3 Distribution Channel
- 5.4.3.4 Application
- 5.4.4 South Korea
- 5.4.4.1 Vaccine Type
- 5.4.4.2 Route of Administration
- 5.4.4.3 Distribution Channel
- 5.4.4.4 Application
- 5.4.5 Rest of APAC
- 5.4.5.1 Vaccine Type
- 5.4.5.2 Route of Administration
- 5.4.5.3 Distribution Channel
- 5.4.5.4 Application
- 5.4.1 China
- 5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
- 5.5.1.1 Vaccine Type
- 5.5.1.2 Route of Administration
- 5.5.1.3 Distribution Channel
- 5.5.1.4 Application
- 5.5.2 United Kingdom
- 5.5.2.1 Vaccine Type
- 5.5.2.2 Route of Administration
- 5.5.2.3 Distribution Channel
- 5.5.2.4 Application
- 5.5.3 France
- 5.5.3.1 Vaccine Type
- 5.5.3.2 Route of Administration
- 5.5.3.3 Distribution Channel
- 5.5.3.4 Application
- 5.5.4 Italy
- 5.5.4.1 Vaccine Type
- 5.5.4.2 Route of Administration
- 5.5.4.3 Distribution Channel
- 5.5.4.4 Application
- 5.5.5 Spain
- 5.5.5.1 Vaccine Type
- 5.5.5.2 Route of Administration
- 5.5.5.3 Distribution Channel
- 5.5.5.4 Application
- 5.5.6 Rest of Europe
- 5.5.6.1 Vaccine Type
- 5.5.6.2 Route of Administration
- 5.5.6.3 Distribution Channel
- 5.5.6.4 Application
- 5.5.1 Germany
- 5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
- 5.6.1.1 Vaccine Type
- 5.6.1.2 Route of Administration
- 5.6.1.3 Distribution Channel
- 5.6.1.4 Application
- 5.6.2 United Arab Emirates
- 5.6.2.1 Vaccine Type
- 5.6.2.2 Route of Administration
- 5.6.2.3 Distribution Channel
- 5.6.2.4 Application
- 5.6.3 South Africa
- 5.6.3.1 Vaccine Type
- 5.6.3.2 Route of Administration
- 5.6.3.3 Distribution Channel
- 5.6.3.4 Application
- 5.6.4 Rest of MEA
- 5.6.4.1 Vaccine Type
- 5.6.4.2 Route of Administration
- 5.6.4.3 Distribution Channel
- 5.6.4.4 Application
- 5.6.1 Saudi Arabia
6 Market Strategy
- 6.1 Demand-Supply Gap Analysis
- 6.2 Trade & Logistics Constraints
- 6.3 Price-Cost-Margin Trends
- 6.4 Market Penetration
- 6.5 Consumer Analysis
- 6.6 Regulatory Snapshot
7 Competitive Intelligence
- 7.1 Market Positioning
- 7.2 Market Share
- 7.3 Competition Benchmarking
- 7.4 Top Company Strategies
8 Company Profiles
- 8.1 Sanofi S.A.
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
- 8.2 GSK plc
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
- 8.3 Sinovac Biotech Ltd
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
- 8.4 Serum Institute of India Pvt. Ltd
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
- 8.5 Zydus Group
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
- 8.6 Takeda Pharmaceutical Company Limited
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
- 8.7 Biological E Limited
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
- 8.8 Shanghai Institute of Biological Products Co., Ltd
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
- 8.9 Daiichi Sankyo Co., Ltd.
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
- 8.10 Merck & Co., Inc.
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
9 About Us
- 9.1 About Us
- 9.2 Research Methodology
- 9.3 Research Workflow
- 9.4 Consulting Services
- 9.5 Our Clients
- 9.6 Client Testimonials
- 9.7 Contact Us
